Fortrea Holdings Inc. (FTRE)
NASDAQ: FTRE · Real-Time Price · USD
10.76
+0.16 (1.51%)
At close: Apr 28, 2026, 4:00 PM EDT
10.64
-0.12 (-1.12%)
After-hours: Apr 28, 2026, 6:51 PM EDT
Fortrea Holdings Revenue
In the year 2025, Fortrea Holdings had annual revenue of $2.72B with 1.00% growth. Fortrea Holdings had revenue of $660.50M in the quarter ending December 31, 2025, a decrease of -5.24%.
Revenue (ttm)
$2.72B
Revenue Growth
+1.00%
P/S Ratio
0.37
Revenue / Employee
$190,448
Employees
14,300
Market Cap
1.01B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 2.72B | 27.00M | 1.00% |
| Dec 31, 2024 | 2.70B | -27.00M | -0.99% |
| Dec 31, 2023 | 2.72B | 27.00M | 1.00% |
| Dec 31, 2022 | 2.70B | -146.10M | -5.14% |
| Dec 31, 2021 | 2.84B | 262.20M | 10.16% |
| Dec 31, 2020 | 2.58B | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Xeris Biopharma Holdings | 291.85M |
| Maravai LifeSciences Holdings | 185.74M |
| Geron | 183.88M |
| Xencor | 125.58M |
| CytomX Therapeutics | 76.20M |
| KalVista Pharmaceuticals | 73.62M |
| Janux Therapeutics | 10.00M |
| Inventiva | 7.94M |
FTRE News
- 7 days ago - Fortrea Announces Date for First Quarter 2026 Financial Results and Conference Call - GlobeNewsWire
- 21 days ago - Fortrea Unveils Fortrea Intelligent Technology™ to Help Sponsors and Sites Run Smarter, More Integrated Trials - GlobeNewsWire
- 7 weeks ago - Fortrea Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 2 months ago - Fortrea Holdings Earnings Call Transcript: Q4 2025 - Transcripts
- 2 months ago - Fortrea Reports Fourth Quarter and Full-Year 2025 Results; Issues Full-Year 2026 Guidance - GlobeNewsWire
- 2 months ago - Fortrea Expands Executive Team, Appointing Oren Cohen as Chief Medical Officer and Scott Dove as President of Clinical Pharmacology Services - GlobeNewsWire
- 3 months ago - Fortrea Announces Date for Fourth Quarter and Full Year 2025 Financial Results and Conference Call - GlobeNewsWire
- 3 months ago - Fortrea Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Fortrea Holdings, Inc. - FTRE - PRNewsWire